Close
16/03/2017
​A new class of inhibitors against pain investigated at the ALBA synchrotron
The pharmaceutical company ESTEVE (2,470 people, 916 million Euros income in 2016), the Universitat Autònoma de Barcelona (UAB) and the ALBA Synchrotron joined together to investigate the mechanism of action of new inhibitors against pain developed by the company.

Getting new information about the interactions, active site and mechanism of action of the developed drugs and the therapeutic target may help to the better understanding of the effects of the inhibitors and can provide key information to improve their properties. In that sense, the XALOC ALBA beam line offers a valuable tool for carrying out the corresponding experiments.

As a first step, the research will be carried out at the Protein Production Platform of the UAB to obtain the pure protein complexed with the inhibitors. Secondly, X-ray crystallography studies will be performed at the biolab and in ALBA.

This project is a good example of public-private collaboration that fosters the synergies and relationships between the industrial and academic sectors to advance research and innovation.

More news

30/04/2015 The Library Living Lab opens its doors 23/04/2015 8 million Euros turnover for the Start-ups settled in the PRUAB 16/04/2015 The BSP opens its new head office 09/04/2015 Three important projects awarded to SENER 25/03/2015 ALBA synchrotron supports the pharmaceutical industry 20/03/2015 Barcelona named top smart city in the world
33 34 35 36 37 38 39 40 41 42 43